BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 29250979)

  • 1. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids.
    Ferrero S; Vellone VG; Barra F
    Expert Opin Drug Metab Toxicol; 2018 Jan; 14(1):107-116. PubMed ID: 29250979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
    Szamatowicz M; Kotarski J
    Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of treatment of uterine fibroids with the selective progesterone receptor modulator, ulipristal acetate.
    Donnez J; Donnez O; Dolmans MM
    Expert Opin Drug Saf; 2016 Dec; 15(12):1679-1686. PubMed ID: 27740868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulipristal acetate for uterine fibroid-related symptoms.
    Puchar A; Luton D; Koskas M
    Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids.
    Tafi E; Scala C; Leone Roberti Maggiore U; Bizzarri N; Candiani M; Venturini PL; Ferrero S
    Expert Opin Drug Saf; 2015 Jun; 14(6):965-77. PubMed ID: 25772793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
    Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
    Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Application of ulipristal acetate in female patients with uterine fibroids.
    Grzechocinska B; Gadomska H; Zygula A; Wielgos M
    Neuro Endocrinol Lett; 2014; 35(3):175-8. PubMed ID: 24977963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The place of selective progesterone receptor modulators in myoma therapy.
    Donnez J; Donnez O; Courtoy GE; Dolmans MM
    Minerva Ginecol; 2016 Jun; 68(3):313-20. PubMed ID: 26930390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical pharmacology and pharmacokinetics of ulipristal acetate for the treatment of uterine fibroids.
    Pohl O; Zobrist RH; Gotteland JP
    Reprod Sci; 2015 Apr; 22(4):476-83. PubMed ID: 25228633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ulipristal acetate for uterine fibroids: 2 years of real world experience in a UK hospital.
    Woodhead N; Pounds R; Irani S; Pradhan P
    J Obstet Gynaecol; 2018 Aug; 38(6):813-817. PubMed ID: 29526144
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of uterine fibroids with ulipristal acetate ☆.
    Donnez J; Vázquez F; Tomaszewski J; Nouri K; Bouchard P; Fauser BC; Barlow DH; Palacios S; Donnez O; Bestel E; Osterloh I; Loumaye E;
    Fertil Steril; 2014 Jun; 101(6):1565-73.e1-18. PubMed ID: 24630081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging treatment options for uterine fibroids.
    Donnez J; Arriagada P; Donnez O; Dolmans MM
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):17-23. PubMed ID: 29486606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vilaprisan for treating uterine fibroids.
    Melis GB; Neri M; Piras B; Paoletti AM; Ajossa S; Pilloni M; Marotto MF; Corda V; Saba A; Giancane E; Mais V
    Expert Opin Investig Drugs; 2018 May; 27(5):497-505. PubMed ID: 29718788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factor for volume reduction of uterine fibroids after short-term use of ulipristal acetate.
    Yun BS; Seong SJ; Jung YW; Kim ML; Bae HS; Kim MK; Shim SS
    Eur J Obstet Gynecol Reprod Biol; 2018 May; 224():133-136. PubMed ID: 29602142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ulipristal Acetate: A Review in Symptomatic Uterine Fibroids.
    Garnock-Jones KP; Duggan ST
    Drugs; 2017 Oct; 77(15):1665-1675. PubMed ID: 28900897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
    Pérez-López FR
    Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic evaluation of ulipristal acetate for uterine leiomyoma treatment.
    Melis GB; Piras B; Marotto MF; Orru' MM; Maricosu G; Pilloni M; Guerriero S; Angiolucci M; Lello S; Paoletti AM
    Expert Opin Drug Metab Toxicol; 2012 Jul; 8(7):901-8. PubMed ID: 22681335
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Applicability of selective progesterone receptor modulators in the treatment of uterine leiomyomata and their future role in the field of gynecology].
    Brazert M; Korman MP; Pawelczyk LA
    Ginekol Pol; 2013 Sep; 84(9):794-800. PubMed ID: 24191519
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
    Talaulikar VS; Manyonda I
    Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ulipristal acetate versus placebo for fibroid treatment before surgery.
    Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
    N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.